CompletedPhase 1NCT00246467

One Year Study to Evaluate Three Different Adjuvanted Doses of the Recombinant Plague Vaccine (rF1 and rV Antigens)

Studying Plague

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
PharmAthene UK Limited
Principal Investigator
Eric Sheldon, MD
Miami Clinical Research
Intervention
Alhydrogel(biological)
Enrollment
123 target
Eligibility
18-55 years · All sexes
Timeline
20052007

Study locations (10)

Collaborators

National Institute of Allergy and Infectious Diseases (NIAID)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00246467 on ClinicalTrials.gov

Other trials for Plague

Additional recruiting or active studies for the same condition.

See all trials for Plague

← Back to all trials